TIMP1 and pancreatic neoplasm: Many studies focused on combination panels for pancreatic cancer screening, such as combining carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) [46,47,48], osteopontin [49], or matrix metallopeptidase 7 with CA19-9 [50], or combining CEA, matrix metalloproteinases 1 (TIMP-1), and CA19-9 [51] or haptoglobin, serum amyloid A, and CA19-9 [52].